Fundz
Real-time · AI · Cross-signal

Biogen just made a move. Here's exactly what to do next.

Who to reach, what to say, and why now — on Biogen, plus every M&A move, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your planRequest a demo

Everyone else gives you a piece

✕Crunchbase & PitchBook list the company — No person, no timing, no opener.
✕ZoomInfo & Apollo sell you a contact — No trigger, no reason to reach out now.
✕LinkedIn Sales Navigator shows you people — No real-time signal, no opener.
✕Clay enriches lists you built — No live signal of its own, no who or when.
✕ChatGPT & gen-AI tools answer on a delay — No live data, no verified contact.
Who to contactWhat to sayWhen to reach outWhy now

Only Fundz delivers all four.

Biogen to acquire Apellis Pharmaceuticals

PUBLIC · BIIBMay 04, 2026•22 days ago

Acquiring Company

Biogen

Acquired Company

Apellis Pharmaceuticals

CambridgeWalthamBiotechnologyHealth CareBiotechnology ResearchBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharma

Description

Apellis Pharmaceuticals, Inc. has announced a merger with Biogen Inc., with new executive compensation plans linked to the transaction. The amendment to the executive separation plan indicates greater retention certainty for executives amid the merger. Key equity awards will vest immediately under certain conditions, potentially impacting shareholder value. The merger is expected to significantly shape both companies' futures.

Company Information

Company

Biogen

Location

Cambridge, Massachusetts, United States

About

Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world. We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Twitter, LinkedIn, Facebook, YouTube.

Predictive Intelligence
Strategic

ML-powered predictions for Biogen's next move

Learn about Strategic plan

Related People

Choose your plan to reveal verified contacts

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed